Home›Trial›NCT04104672
🔬NCT04104672Phase 1ACTIVE NOT RECRUITING

A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Study Summary

This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer.

Conditions
Advanced Pancreatic Cancer
Interventions / Drugs
AB680ZimberelimabNab-paclitaxelGemcitabine
View on ClinicalTrials.gov ↗
Sponsor
ARQT
Arcus Biosciences
Immuno-Oncology
F29/100
Study Details
Enrollment196 participants
Primary Completion—
Lead SponsorArcus Biosciences, Inc.
Data Retrieved2026-04-11 02:54:25.662871+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.